85 related articles for article (PubMed ID: 20861668)
1. Malaria vaccine development based on merozoite surface proteins of Plasmodium falciparum.
Chauhan VS; Yazdani SS; Gaur D
Hum Vaccin; 2010 Sep; 6(9):. PubMed ID: 20861668
[TBL] [Abstract][Full Text] [Related]
2. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.
Woehlbier U; Epp C; Kauth CW; Lutz R; Long CA; Coulibaly B; Kouyaté B; Arevalo-Herrera M; Herrera S; Bujard H
Infect Immun; 2006 Feb; 74(2):1313-22. PubMed ID: 16428781
[TBL] [Abstract][Full Text] [Related]
3. Malaria vaccine.
Khurana SK; Talib VH
Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
[TBL] [Abstract][Full Text] [Related]
4. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.
Kaushal DC; Kaushal NA; Narula A; Kumar N; Puri SK; Dutta S; Lanar DE
Indian J Biochem Biophys; 2007 Dec; 44(6):429-36. PubMed ID: 18320841
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium falciparum 19 kDa of merozoite surface protein-1 (MSP-1(19)) expressed in Mycobacterium bovis bacille Calmette Guerin (BCG) is reactive with an inhibitory but not a blocking monoclonal antibody.
Nurul AA; Rapeah S; Norazmi MN
Trop Biomed; 2010 Apr; 27(1):60-7. PubMed ID: 20562815
[TBL] [Abstract][Full Text] [Related]
7. Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species.
O'Donnell RA; Saul A; Cowman AF; Crabb BS
Nat Med; 2000 Jan; 6(1):91-5. PubMed ID: 10613831
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development.
Cowman AF; Baldi DL; Duraisingh M; Healer J; Mills KE; O'Donnell RA; Thompson J; Triglia T; Wickham ME; Crabb BS
Philos Trans R Soc Lond B Biol Sci; 2002 Jan; 357(1417):25-33. PubMed ID: 11839179
[TBL] [Abstract][Full Text] [Related]
9. The malaria vaccine development program in Papua New Guinea.
Genton B; Anders RF; Alpers MP; Reeder JC
Trends Parasitol; 2003 Jun; 19(6):264-70. PubMed ID: 12798084
[TBL] [Abstract][Full Text] [Related]
10. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.
Genton B; Betuela I; Felger I; Al-Yaman F; Anders RF; Saul A; Rare L; Baisor M; Lorry K; Brown GV; Pye D; Irving DO; Smith TA; Beck HP; Alpers MP
J Infect Dis; 2002 Mar; 185(6):820-7. PubMed ID: 11920300
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism in msp-2, ama-1 and csp genes in Plasmodium falciparum field isolates from north and north-western India.
Farooq U; Malla N; Dubey ML
J Vector Borne Dis; 2009 Jun; 46(2):109-16. PubMed ID: 19502690
[TBL] [Abstract][Full Text] [Related]
12. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
Daubenberger CA; Nickel B; Ciatto C; Grütter MG; Pöltl-Frank F; Rossi L; Siegler U; Robinson J; Kashala O; Patarroyo ME; Pluschke G
Eur J Immunol; 2002 Dec; 32(12):3667-77. PubMed ID: 12516559
[TBL] [Abstract][Full Text] [Related]
13. A PCR method for molecular epidemiology of Plasmodium falciparum Msp-1.
Tanabe K; Sakihama N; Kaneko O; Saito-Ito A; Kimura M
Tokai J Exp Clin Med; 1998 Dec; 23(6):375-81. PubMed ID: 10622635
[TBL] [Abstract][Full Text] [Related]
14. Strain-specific immunity may drive adaptive polymorphism in the merozoite surface protein 1 of the rodent malaria parasite Plasmodium chabaudi.
Cheesman S; Tanabe K; Sawai H; O'Mahony E; Carter R
Infect Genet Evol; 2009 Mar; 9(2):248-55. PubMed ID: 19121414
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism in Plasmodium falciparum vaccine candidate antigens.
Mahajan RC; Farooq U; Dubey ML; Malla N
Indian J Pathol Microbiol; 2005 Oct; 48(4):429-38. PubMed ID: 16366089
[TBL] [Abstract][Full Text] [Related]
16. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
[TBL] [Abstract][Full Text] [Related]
17. The development of malaria vaccines: SPf66--what next?
Tanner M; Alonso PL
Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632
[TBL] [Abstract][Full Text] [Related]
18. Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children.
Høgh B
Scand J Infect Dis Suppl; 1996; 102():1-53. PubMed ID: 9060051
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
20. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
Chang SP; Nikaido CM; Hashimoto AC; Hashiro CQ; Yokota BT; Hui GS
J Immunol; 1994 Apr; 152(7):3483-90. PubMed ID: 8144929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
